Grifols (GRFS) Enterprise Value (2009 - 2025)
Grifols' (GRFS) quarterly Enterprise Value came in at -$51.2 million in Q4 2025, up 96.07% YoY from -$26.1 million in Q4 2024, and up 96.07% on a QoQ basis from -$1.3 billion in Q4 2024.
Grifols (GRFS) Enterprise Value (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Enterprise Value data on file, last reported at -$51.2 million in Q4 2025.
- Quarterly Enterprise Value rose 96.07% year-over-year to -$51.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$51.2 million (up 96.07% YoY) and the FY2025 annual result came in at -$51.2 million, up 96.07% from the prior year.
- Enterprise Value advanced to -$51.2 million in Q4 2025, from -$1.3 billion in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$51.2 million in Q4 2025 to a low of -$3.1 billion in Q4 2021.
- A 5-year average of -$1.1 billion and a median of -$604.7 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value sank 335.16% — and 2025, when it surged 96.07%.
- Tracing GRFS's Enterprise Value over 5 years: stood at -$3.1 billion in 2021, then surged by 80.27% to -$604.7 million in 2022, then climbed by 1.66% to -$594.6 million in 2023, then plunged by 119.07% to -$1.3 billion in 2024, then jumped by 96.07% to -$51.2 million in 2025.
- The last three Enterprise Value figures came in at -$51.2 million (Q4 2025), -$1.3 billion (Q4 2024), and -$594.6 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.97 Bn | 633.21 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 470.43 Bn | 463.86 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 376.87 Bn | 369.73 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 303.36 Bn | 295.67 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 257.56 Bn | 252.66 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 236.76 Bn | 222.77 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 182.01 Bn | 178.83 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 159.37 Bn | 147.67 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 106.08 Bn | 101.91 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Grifols | 5.44 Bn | 4.44 Bn | - | -1.00 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -51.22 Mn |
| Dec 31, 2024 | -1.30 Bn |
| Dec 31, 2023 | -594.61 Mn |
| Dec 31, 2022 | -604.66 Mn |
| Dec 31, 2021 | -3.07 Bn |
| Dec 31, 2020 | -704.36 Mn |
| Sep 30, 2020 | 835.58 Mn |
| Mar 31, 2020 | 1.12 Bn |
| Dec 31, 2019 | 2.03 Bn |
| Sep 30, 2019 | -305.89 Mn |
| Mar 31, 2019 | -858.09 Mn |
| Dec 31, 2018 | -703.91 Mn |
| Sep 30, 2018 | -734.00 Mn |
| Jun 30, 2018 | -316.02 Mn |
| Mar 31, 2018 | -468.22 Mn |
| Dec 31, 2017 | -1.05 Bn |
| Jun 30, 2017 | -2.97 Bn |
| Dec 31, 2016 | -962.14 Mn |
| Sep 30, 2016 | -557.00 Mn |
| Jun 30, 2016 | -1.27 Bn |